U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07174570) titled 'Celecoxib, Durvalaumab and Tremellimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer' on Sept. 11.
Brief Summary: This phase II trial tests how well the combination of celecoxib with durvalaumab and tremellimumab works in treating patients with hepatocellular cancer (liver cancer) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Celecoxib belongs to the family of drugs called nonsteroidal anti-inflammatory agents and is used to reduc...